NCT07225751 A Prospective, Randomized, Single-blind, Controlled, Multi-center Study to Assess the Safety and Performance of MagnetOsTM Compared to Autogenous Bone Graft in Patients Undergoing Hindfoot or Ankle Fusions.
| NCT ID | NCT07225751 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Kuros Biosurgery AG |
| Condition | Ankle Arthrodesis or Arthroplasty |
| Study Type | INTERVENTIONAL |
| Enrollment | 126 participants |
| Start Date | 2025-11-25 |
| Primary Completion | 2028-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 126 participants in total. It began in 2025-11-25 with a primary completion date of 2028-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a phase IV post-marketing study for MagnetOs Putty and MagnetOs Easypack Putty. MagnetOs is a synthetic bone graft extender product that is routinely used by surgeon as treatment for hindfoot and ankle disorders. In this study, MagnetOs Putty and MagnetOs Easypack Putty will be use according to the latest Instructions For Use, standalone in the foot and ankle.
Eligibility Criteria
Inclusion: 1. Patient is able to read/be read, understand, and provide written informed consent and has signed the IRB approved informed consent. 2. Male or female patient ≥ 18 (considered skeletally mature) up to and including 75 years old 3. Patients requiring one of the following hindfoot fusion procedures, using surgical technique, necessitating rigid hardware fixation and supplemental bone graft/ substitute: ankle fusion (tibiotalar) subtalar fusion (talocalcaneal), calcaneocuboid fusion, talonavicular fusion, OR double fusion (any combination of any two of the following: subtalar, talonavicular and calcaneocuboid joints). 4. Hardware parameters - rigid fixation using screws, plates, staples, nails or a combination. Exclusion: 1. Expected to need secondary intervention within one year following surgery. 2. Had prior fusion or attempted fusion of the joints to be fused. 3. Patient is not ambulatory. 4. Surgical technique where bone graft is not expected to be used. 5. Conditions at the surgeon's discretion in which general bone grafting is not advisable. 6. Radiographic evidence of fractures or pathologies around the fusion that could negatively impact the fusion process (e.g., growth plate fracture around the fusion or bone cysts). 7. Significant vascular impairment proximal to the graft site. 8. Acute and/or chronic infections in the operated area (soft tissue infections; bacterial bone diseases; osteomyelitis) 9. Pre-existing sensory impairment (e.g. diabetes, Charcot). Diabetics patients with HbA1c greater than 7.0 OR that were not sensitive to the 5.07 monofilament will be excluded. 10. Metabolic disorders know to adversely affect the skeleton (e.g., renal osteodystrophy or hypercalcemia). 11. If intraoperative soft tissue coverage is not planned or possible. 12. Receiving treatment with medication interfering with calcium metabolism (chronic use of glucocorticoid and use high dose NSAIDs 800 mg TID for \> the first 6 weeks post-op). 13. Has benign or malignant tumor at the surgical site. 14. Has history or presence of active malignancy (non-invasive skin cancer is allowed). 15. Has known substance abuse, psychiatric disorder, or a condition which, in the opinion of the investigator, may influence the healing or ability to comply with protocol requirements (e.g. prisoners, physically or mentally compromised, etc.). 16. Is involved in active litigation relating to his/her foot and ankle condition. 17. Participation in an investigational study within 30 days prior to surgery for study devices. 18. Patient with body mass index (BMI) \> 50. 19. Patient cannot comply with all post-operative evaluation and visits . 20. Any pre-existing condition that the surgeon determines could interfere with the patient's ability to perform objective functional measurements. 21. Women who are or intend to become pregnant within the next 12 months.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07225751 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Ankle Arthrodesis or Arthroplasty. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07225751 currently recruiting?
Yes, NCT07225751 is actively recruiting participants. Contact the research team at cesar.silva@kurosbio.com for enrollment information.
Where is the NCT07225751 trial being conducted?
This trial is being conducted at Vail, United States, Columbus, United States, Charlotte, United States, Philadelphia, United States and 2 additional locations.
Who is sponsoring the NCT07225751 clinical trial?
NCT07225751 is sponsored by Kuros Biosurgery AG. The trial plans to enroll 126 participants.